SOD1 gene screening in ALS – frequency of mutations, patients' attitudes to genetic information and transition to tofersen treatment in a multi-center program
Thomas Meyer Peggy Schumann Torsten Grehl Ute Weyen Susanne Petri Annekathrin Rödiger Robert Steinbach Julian Grosskreutz Sarah Bernsen Patrick Weydt Joachim Wolf René Günther Maximilian Vidovic Petra Baum Moritz Metelmann Jochen H. Weishaupt Berthold Streubel David C. Kasper Yasemin Koc Dagmar Kettemann Jenny Norden Philipp Schmitt Bertram Walter Christoph Münch Susanne Spittel André Maier Péter Körtvélyessy 1 Department of Neurology,Center for ALS and other Motor Neuron Disorders,Charité – Universitätsmedizin Berlin,Corporate Member of Freie Universität Berlin,Humboldt-Universität zu Berlin,and Berlin Institute of Health,Berlin,Germany2 Ambulanzpartner Soziotechnologie APST GmbH,Berlin,Germany3 Department of Neurology,Center for ALS and other Motor Neuron Disorders,Alfried Krupp Krankenhaus,Essen,Germany4 Department of Neurology,Center for ALS and other Motor Neuron Disorders,Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil,Bochum,Germany5 Department of Neurology,Hannover Medical School,Hannover,Germany6 Department of Neurology,Jena University Hospital,Jena,Germany7 ZSE,Zentrum für Seltene Erkrankungen,Jena University Hospital,Jena,Germany8 Department of Neurology,Universitätsmedizin Schleswig-Holstein,Lübeck,Germany9 Department for Neuromuscular Disorders,Bonn University,Bonn,Germany10 DZNE,Deutsches Zentrum für Neurodegenerative Erkrankungen,Bonn,Germany11 Department of Neurology,Diako Mannheim,Mannheim,Germany12 Department of Neurology,Technische Universität Dresden,University Hospital Carl Gustav Carus,Dresden,Germany13 DZNE,Deutsches Zentrum für Neurodegenerative Erkrankungen,Dresden,Germany14 Department of Neurology,University Hospital Leipzig,Leipzig,Germany15 Division for Neurodegenerative Diseases,Neurology Department,University Medicine Mannheim,Heidelberg University,Mannheim Center for Translational Medicine,Mannheim,Germany16 Medical University of Wien,Institute for Pathology,Wien,Austria17 ARCHIMED Life Science GmbH,Wien,Austria
DOI: https://doi.org/10.1080/21678421.2024.2401131
2024-09-14
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Abstract:Objective : To report the frequency of pathogenic SOD1 gene variants in a screening program in amyotrophic lateral sclerosis (ALS), and the clinical practice of transition to an expanded access program (EAP) of tofersen treatment. Methods : From October 2021 to February 2024, at 11 ALS centers in Germany genetic testing for SOD1 , FUS , TARDBP, and C9orf72 was performed. Patients were offered to opt for notification either about all genetic variants or SOD1 variants relevant for tofersen therapy. The transition to the EAP with tofersen was assessed. Results : 1935 patients were screened (94.7% sporadic ALS). 48.8% ( n = 928) opted for notification of treatment-relevant information. Genetic variants were found as follows: SOD1 (likely) pathogenic variants (class 4/5) 1.8% ( n = 34), variants of unknown significance (class 3) 0.8% ( n = 16), FUS (class 4/5) 0.9% ( n = 17) , TARDBP (class 4/5) 1.3% ( n = 25), C9orf72 hexanucleotide repeat expansion 7.0% ( n = 135). In SOD1 -ALS (encompassing class 3–5 variants, n = 50), 68.0% ( n = 34) reported a negative family history. 74.0% ( n = 37) of SOD1 -ALS patients – which represent 1.9% of all participants of the screening program – were transitioned to tofersen. Median duration from start of genetic testing to treatment was 94 days (57 to 295 days). Eight patients declined treatment whereas five individuals died before initiation of therapy. Conclusion : The finding of SOD1 variants in patients with a negative family history underscores the need for a broad genetic screening in ALS. In SOD1 -ALS, the treatment option with tofersen was mostly utilized. The wide range in the transition time to tofersen calls for a SOD1 -ALS management program.
clinical neurology